# OnCo record nalirifox (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nalirifox/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nalirifox" ;
  schema:name "NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)"@en ;
  schema:description "NALIRIFOX is a version of FOLFIRINOX using a liposome-wrapped irinotecan, approved in 2024 as a first-line option for metastatic pancreatic cancer."@en ;
  schema:url <https://onco.cc/drugs/nalirifox/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://www.onclive.com/view/fda-approves-frontline-nalirifox-for-metastatic-pancreatic-adenocarcinoma>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ONIVYDE%22>, <https://www.nice.org.uk/guidance/terminated/ta1052> ;
  onco:status "approved" ;
  onco:modality "Cytotoxic regimen" ;
  schema:alternateName "Onivyde regimen" ;
  onco:approval "US 2024: First-line metastatic pancreatic adenocarcinoma", "EU 2016: Onivyde 2L after gemcitabine (2016); NALIRIFOX label 2025", "EU 2025: First-line treatment of metastatic adenocarcinoma of the pancreas (Onivyde pegylated liposomal with oxaliplatin, fluorouracil and leucovorin), listed in the EMA therapeutic indications read on 24 September 2026; the year is the corpus's regional row for the label extension" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/topoisomerase-inhibitors/>, <https://onco.cc/technologies/platinum/> ;
  onco:companies <https://onco.cc/companies/ipsen/> ;
  onco:terms <https://onco.cc/terms/prodrug/> ;
  onco:trials <https://onco.cc/trials/napoli-3/>, <https://onco.cc/trials/rasolute-302/> .